

Philipp Mann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1499709/publications.pdf>

Version: 2024-02-01

16
papers

506
citations

933447

10
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

799
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 329-340.	9.1	103
2	Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 931-941.	1.9	79
3	The Triple A Syndrome Is Due to Mutations in ALADIN, a Novel Member of the Nuclear Pore Complex. <i>Endocrine Research</i> , 2004, 30, 891-899.	1.2	66
4	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV</i> , the, 2020, 7, e688-e698.	4.7	58
5	Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0119629.	2.5	43
6	Mice Lacking the Nuclear Pore Complex Protein ALADIN Show Female Infertility but Fail To Develop a Phenotype Resembling Human Triple A Syndrome. <i>Molecular and Cellular Biology</i> , 2006, 26, 1879-1887.	2.3	41
7	Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. <i>PLoS ONE</i> , 2018, 13, e0206838.	2.5	25
8	Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost. <i>Journal of Infectious Diseases</i> , 2017, 216, 1080-1090.	4.0	23
9	Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. <i>PLoS ONE</i> , 2016, 11, e0155702.	2.5	22
10	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. <i>Clinical Infectious Diseases</i> , 2020, 72, 50-60.	5.8	15
11	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117.	8.4	8
12	Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen. <i>Journal of Virology</i> , 2017, 91, .	3.4	7
13	Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, Randomised, Observer-Blinded, Placebo-Controlled Clinical Trial in Ten Countries in Europe and Latin America. <i>SSRN Electronic Journal</i> , 0, , .	0.4	7
14	A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant. <i>Vaccines</i> , 2022, 10, 508.	4.4	5
15	High prevalence of ST-elevation, early repolarization, and left ventricular hypertrophy during the eligibility assessment for an HIV vaccine trial in young, healthy Tanzanians. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2017, 26, 1-6.	1.0	3
16	Safety and Immunogenicity of mRNA-LNP COVID-19 Vaccine CVnCoV in Latin American Adults; A Phase 2 Randomized Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1